

Index

- Abbott Laboratories, 145
- Acquihires, 34
- Acquisitions. *See also* Mergers
in biotechnology sector, 63
courts should require evidence of
benefits from, 237–238
courts should require scrutiny of
acquisitions that eliminate potential
competitors, 238–239
effect on competition and innovation,
34–35, 38, 237
enforcement of patent acquisitions, 36, 37
by high-tech platforms, 31–34
incumbent success in bidding wars, 50,
62–64
in innovation cases where not necessary
to incentivize innovation, 105
of nascent competitors, 170, 177, 187
study of in pharmaceutical industry,
125–130
- Adjustment costs, organizational failures
and, 7, 71–75
- AdMeld, 32
- AdMob, 32, 34
- Adobe PhotoShop, 182
- Adobe’s Portable Document Format
(PDF), 219
- Advanced Micro Devices (AMD),
competition and innovation in
microprocessors and, 120–121
- Advertising
internet searches and, 10, 15, 24, 32, 197,
201, 202
mobile, 32, 34
- Agency theories, separation between
corporate ownership and managerial
control, 69–71, 75
- Alcatel, 131
- Allied Orthopedic Appliances v. Tyco Health
Care Group*, 208–209
- Allied Tube & Conduit Corp. v. Indian Head*,
228–229
- Allison Transmission Division of General
Motors, proposed merger with ZF
Friedrichshafen, 2–3, 145
- Alphabet, 5. *See also* Google
acquisitions, 31, 33
European Commission fines, 196, 204
as technology platform, 20
- Alstom, 163
- AltaVista, 19
- Amazon, 5, 15
acquisitions, 32–33
investment in Nucleus, 31
preferential placement for private label
products, 10, 243
price war with Quidsi, 251n56
as technology platform, 20
- Amdahl, 134
- American Home Products–American
Cyanamid merger, 151
- American National Standard (ANS), 224
- American National Standards Institute
(ANSI), 220, 221
- Amgen–Immunex merger, 158–159
- Andreessen, Marc, 168
- Android phones and operating system, 19
European Commission case against
Google and, 223–224
- Antitrust enforcement
ability to address complexities of
high-tech markets, 14, 15–16
addressing innovation in enforcement
decisions, 2

- Antitrust enforcement (cont.)
 - competition in high-technology economy and, 1–2
 - cumulative innovation and, 68
 - does high-tech economy need more aggressive, 30–35
 - evaluating effectiveness of remedies for innovation, 241–242
 - limits on policy that can influence innovation, 7
 - for mergers (*see* Merger enforcement for innovation)
 - networks effects and, 19–20
 - question of whether to break up big tech, 242–244
 - for standard-setting, 27–28, 222–232
- Antitrust enforcement matrix for mergers in high-tech industries, 78–79
- Antitrust enforcement pyramid for mergers with potential harm to innovation, 96, 97
- Antitrust Guidelines for the Licensing of Intellectual Property*, 99, 100, 253n18, 256n6
- Antitrust issues for unilateral standard-setting, 222–228
 - efforts to capture value from standard by exerting proprietary intellectual property rights, 224–228
 - efforts to compel adherence to dominant firm's preferred standard, 223–224
 - efforts to disrupt industrywide compatibility with a standard, 222–223
- Antitrust laws
 - applied to innovation, 2, 35–39, 209
 - flexibility for innovation, 5, 9, 86, 235
 - interacting with intellectual property laws, 24–25
 - monopolization *vs.* high prices and, 227
- Antitrust Modernization Commission, 35, 251n66
- Apache Open Office suite, 182
- Apple, 5
 - acquisitions, 32
 - FairPlay digital rights management technology, 208, 219
 - incentives to advantage own products, 10, 243
 - iPhones, 19, 210
 - management of potentially destructive innovation, 74–75
 - product design and interoperability and, 208
 - as technology platform, 20
- Applications barrier to entry, 168, 171–172, 182–183, 187–190, 222
- middleware and, 172, 181, 183
- Application specific integrated circuits (ASICs), 147
- Appropriability
 - antitrust law and, 38–39
 - technological spillovers and, 89–90
- Appropriation
 - consequences of limited, 42–45
 - innovation cases where appropriation is high, 102–103
 - mergers and, 79, 89, 102
 - technological opportunity and, 110
 - of value from discoveries, 58–59
- Arbitron, 25–26, 94
 - proposed merger with Nielsen Holdings, 153–155
- ARM, 74
- Array BioPharma, 150, 155
- Arrow replacement effect, 6, 8, 41–42, 45–53
 - assumptions of, 47–50
 - earnings from existing products as deterrent to innovation and, 72–73
 - innovation as discrete event and, 55
 - innovation by incumbents and, 118, 119, 120
 - limitations of, 50–53
 - product-to-project mergers and, 93
 - weak antitrust enforcement and, 189
- Artificial intelligence firms, acquired by Google, 32
- Aspen Skiing Co. v. Aspen Highlands Skiing Corp.*, 276n60
- ASTM (formerly American Society for Testing and Materials), 220
- AstraZeneca, 162
- AT&T, 65
 - breakup of, 130–132, 242, 242–243
 - compulsory licensing consent decree and, 132–133, 239
- AT&T Bell Labs, 131
- Auction effect, innovation and 63–64
- Aventis, 157
- Aventis Crop Science, 162

- “Ballot box,” European Commission’s requirement that Microsoft offer browser, 223
- BASF, 164
- Baxter, William, 131
- Bayer, 162, 164
- Beckman Instruments, 73
- Behavioral merger remedies, 7, 9, 79, 114, 118, 140–142, 147
- Bell Communication Research (Bellcore), 131
- Bell Laboratories, 73, 131
- Bell System, dissolution of, 185. *See also* AT&T
- Beluga, 32
- Berkey, 205–206, 212
- Berkey v. Kodak*, 212
- Bidding for R&D assets, 62–64
- Big tech, question of whether antitrust enforcement should break up, 242–244
- Bing, 200
- Biotechnology industries, bidding for R&D assets, 62–64
- Blackberry, 19
- Bluetooth, 233
- Blu-Ray Disc Association, 220
- BMW, 87
- Boeing, 147–148
- BRAF-inhibitor, 155
- Breyer, Stephen, 249n23
- Broadcom, 147
- Brocade Systems, 147
- Browsers, evolution of, 182
- Browser war, 170, 269n14
- Bundling, 183, 272n62, 272n64
- Business Review Letter (BRL), 230–231
- Buy-out, R&D investment and expectation of, 105
- Canon, 74, 134
- Cantab Pharmaceuticals, 152
- CDMA2000, 277n12
- CDNow, 33
- Celtic Pharmaceuticals, 152
- Central processing units (CPUs), 210–211
- Chinese imports, effect on innovation, 115–116, 117
- Chiron, 156
- Chrome browser, 182, 186, 223, 269n14, 272n72
- Ciba-Geigy-Sandoz merger, 95, 156–158
- Cisco, 28, 147
- Citation-weighted patents, inverted-U relationship between competition and patenting, 114–115, 117
- Clayton Act, 3–4, 237
- antitrust market in, 36, 37
- Cloud computing, 188
- Coercion, hard switch and, 206–207
- Collusion, SDOs and, 228–229
- Comparison shopping services (CSS), 195–204, 214–217. *See also* Google comparison shopping services case
- Compatibility
- antitrust policy for standards/conduct affecting, 12
- dominance and, 22
- network effects and, 18, 28
- standards and, 28, 222–228
- Competition. *See also* High-technology economy, competition policy for; Innovation-centric competition policy antitrust law and potential, 37–38 bidding for R&D assets and, 63–64 Clayton Act on mergers and acquisitions lessening, 3 codetermination with firm size and innovation, 109–110 evaluating mergers for innovation and, 86–92 high-technology economy and, 1–2 import, 115–116, 117 importance of protecting nascent, 187–188 innovation and new, 114–116, 117 innovation incentives and, 7, 56 mergers and, 78, 86–92 merger *vs.* reduction in, 91 preemption incentives for, 48–50 product design and, 202, 204–205 Schumpeter on, 41, 42–45 stepwise innovation and, 61–62 theory of imperfect, 6
- Competition and innovation: empirical evidence, 107–137
- conclusions on, 136–137
- divestiture and compulsory licensing, 130–135
- industry studies, 118–122
- interindustry econometric studies, 112–118
- introduction, 107–108

- Competition and innovation (cont.)
 mergers, 122–130
 unraveling the industry-innovation connection, 108–112
- Competition policies, move from price-centric to innovation-centric, 2, 5, 12, 14–15, 235–236,
- Competition policy for innovation and product designs, 10–11, 183, 195–197, 205–218
 applied to Google Shopping case, 214–216
 hard switch, 205–209
 profit sacrifice/no economic sense test, 209–211
 rule of reason, 211–214
- Competition policy for standards, 219–234
 antitrust concerns from collective conduct in SDOs, 228–232
 antitrust issues for unilateral standard-setting, 222–228
 introduction, 219–222
 policies to promote FRAND licensing, 232–234
- Competitive market, incentive to invest in cost-reducing innovation in perfectly, 45–53
- Competitors, complementors *vs.*, 190–191
- Complementors, competitors *vs.*, 190–191
- Complements, evaluation of competition and, 26–28
- Complex instruction computing (CISC) microprocessors, 74
- Compulsory licensing, 68, 137, 141
 effects on industry innovation and price competition, 132–135
 mandated licensing agreements, 9, 25
 as tool to promote innovation, 239–240, 263n66
- Compulsory licensing as merger remedy, 155–161
 Amgen–Immunes, 158–159
 Ciba–Geigy–Sandoz, 156–158
 3D Systems–DTM Corp., 160–161
 Flow International Corp.–OMAX Corp., 159–160
- Comscore Inc., 154, 274n9
- Concentrated industries
 bias toward incremental innovation in existing products, 121–122
 innovations and, 113
- ConnectU, 32
- Conner, 73
- Conscious parallelism, 87
- Consent decrees, 9
 AT&T, 132–133, 239
 IBM, 132, 133–134, 239
 Microsoft and, 10, 174
 Xerox, 132, 133, 134, 239
- Conspiracy, 87
- Consumer harm or benefits
 analyzing mergers for, 82, 85–86, 100
 exclusionary contracts and, 22
 from antitrust enforcement focused on innovation, 31, 237
 Google’s ability to degrade search results and, 200–201
 internet searches and quality costs to, 199–200
 network effects and, 22
 standards and benefits for, 222
 zero prices and, 199
- Consumer welfare
 antitrust enforcement and, 1–2, 235
 exclusionary practices and, 22, 23
 monopoly innovation incentives and, 52
 network effects and, 19
 price coordination and, 50
- Consumer welfare analysis
 rule of reason analysis and, 212
- Control Data, 73, 134
- Coordinated interaction, lessening of competition on prices and R&D, 86–87
- Copiers, Xerox consent decree and innovation in, 134
- Cost of entry into new markets, 29–30
- Cournot complements effect, 27, 50–51, 185
 product-to-project mergers and, 93–94
- Covidien, 150, 162
- Creative destruction
 of high-tech industries, 15–16
 innovation and, 43
- Credence good, internet search and, 200
- CRISPR technology, 66
- Crowley, John, 149, 264n25
- Cumulative innovation, 47, 55, 56–57, 64–68, 254n20
- Curtiss, Glenn, 65
- Customers, failure to innovate due to too much focus on, 71–72
- Cytec, 148

- Dark Blue Labs, 32
- Darwinian selection mechanism, 112, 260n21
- Data
 - antitrust issues and, 25–26
 - privacy concerns, 21, 29–30
- Data aggregation, evaluation of antitrust harms and, 4
- Data limitations, testing innovation relationships and, 110–111
- Decision-theoretic approach, 259n50
- Deep Mind, 32
- Dell Computer, VL computer bus standard and, 225–226
- Department of Justice (DOJ)
 - Allison–ZF merger and, 2–3, 142
 - Antitrust Guidelines for the Licensing of Intellectual Property, 99, 100, 253n18, 256n6
 - Applied Materials–Tokyo Electron merger and, 145–148
 - Heraeus Electro-Nites–Midwest Instrument merger and, 152–153
 - Horizontal Merger Guidelines, 82, 83–86
 - innovation enforcement at European Commission and, 163–164
 - shared merger authority with FTC, 77–78
 - 3D Systems–DTM Corp. merger and, 160–161
 - US v. Microsoft* and, 170, 171–174, 177–179, 181–184
- Differential investment costs, innovation by incumbents and new entrants and, 119
- Digene, 148
- DIRECTV, 22
- Disruptive technology
 - approaches to analyze mergers and, 86
 - innovator’s dilemma and, 71–73
 - relevance to organization theories of innovation, 48
- Divestiture, 130–135
- examples for merger enforcement, 149–155
- as a merger remedy for innovation, 140–141
- targeted, 154, 161, 166
- Dolby Digital standard, 221
- Dominant firms, efforts to compel adherence to preferred standard, 223–224
- DoubleClick, 32
- Dow–DuPont merger, European Commission on, 163–165
- Downward innovation pressures from mergers, 89, 91–93, 101–103, 236, 237
- Drastic innovation, incremental innovation *vs.*, 121–122
- Dropbox, 182
- DTM Corp., proposed merger with 3D Systems, 160–161
- DuckDuckGo, 200
- Duopolies, stepwise innovation model and, 62
- DuPont, European Commission on merger with Dow, 163–165
- Durable goods
 - innovation and, 120–121
 - innovation incentives for, 52–53
 - profiting from additional sales, 119–120
- Dynamic random access memory (DRAMs) devices, 226
- Eastman Kodak Company, anticompetitive product design and, 205–206
- Economic assessment, of US and European antitrust litigation against Microsoft, 176–184
- Economies of scale
 - as a barrier to competition, 189
 - and interoperability standards, 12, 219
 - from R&D, 4, 86, 110
- Economies of scope, 29
- Efficiency defenses related to innovation, 38–39, 84–85
- Egghead Software, 33
- Electrical and Electronic Engineers Standards Association (IEEE-SA), 220
- FRAND updates, 230–231
- eMarketer, 34
- Emission control technologies, collusion on, 87
- Entry barriers. *See also* Applications
 - barrier to entry
 - data as, 25, 239
 - high-tech industries with, 16–17
 - for platform markets, 21
- Environmental Protection Agency, 220
- EOS, 161

- Ericsson, 131
- Ethernet, 72
- European Commission (EC)
- antitrust enforcement at, 216–217
 - antitrust litigation against Microsoft, 170, 174–176, 179–181
 - on dominant firms having duty to help rivals, 176, 180
 - economic assessment of antitrust litigation against Microsoft, 179–181
 - exploration of “big data” issues, 26
 - finest for Intel, 120
 - Google Android case and, 223–224
 - Google Shopping case and, 202–205, 240
 - horizontal merger guidelines, 82, 85, 99
 - innovation enforcement at, 161–165
 - merger challenges by, 141
- European Committee for Standardization, 220
- European Economic Area (EEA), 4
- European Telecommunications Standards Institute (ETSI), 220
- European Union (EU)
- antitrust legislation in, 4
 - General Data Protection Regulations, 30
- Evergreening, 213
- Evidentiary requirements, antitrust law and, 39, 96
- Exclusionary conduct. *See also* Microsoft and innovation harm from exclusionary conduct
- antitrust enforcement and, 19
 - consumer harm and, 22
 - evidence of substantial foreclosure to prevent, 239
 - platforms and, 22–23
- Exclusionary contracting, 178
- Expedia, 33
- Facebook, 5
- acquisitions, 32, 33–34, 243, 250n51
 - benefit of data troves for, 25
 - cloning of Snapchat features, 31
 - cross-platform network effects and, 21
 - Instagram acquisition, 32, 33–34, 35, 243
 - Onavo acquisition, 250n51
 - privacy concerns and, 30
 - replacing MySpace, 19
- Fairchild Semiconductor International, 73
- FairPlay encryption protocol, Apple and, 208, 219
- Federal Communications Commission, 220
- Federal Trade Commission (FTC)
- addressing unfair and deceptive practices, 3–4
 - American Home Product–American Cyanamid merger and, 151
 - Amgen–ImmuneX merger and, 158–159
 - antitrust enforcement at, 216–218
 - Antitrust Guidelines for the Licensing of Intellectual Property, 99, 100, 253n18, 256n6
 - Ciba–Geigy–Sandoz merger and, 156–158
 - complaint against Dell about VL bus standard, 226
 - complaint against Rambus, 226–227
 - Flow International Corp.–OMAX Corp. merger and, 159–160
 - Genzyme–Novazyme merger and, 3
 - Glaxo–Wellcome merger and, 161–162
 - Glaxo Wellcome–SmithKlineBeecham merger and, 151–152
 - Google Shopping case and, 196, 202–205, 214–216, 240
 - Horizontal Merger Guidelines, 82, 83–86
 - innovation enforcement at European Commission and, 161–163
 - Intel complaint, 210–211
 - Nielsen Holdings–Arbitron merger and, 153–155
 - Novartis–GSK merger and, 155
 - settlement with Intel over unfair methods of competition in microprocessor industry, 120
 - shared merger authority with DOJ, 77–78
 - unconditional challenges to proposed Thoratec–HeartWare merger, 143–145
- Federal Trade Commission (FTC) Act, 4
- Firefox, 269n14
- Firm size
- codetermination with innovation and competition, 109–110
 - effect on appropriation and innovation incentives, 43–44
- Flow International Corp.–OMAX Corp. merger, 159–160
- Foundem, 195, 198, 215
- FRAND licensing, 225, 227
- coordination in determination of licensing obligations, 229–232
 - policies to promote, 232–234

- FriendFeed, 32
 Froogle, 195
 Fuji, 74
- Gates, Bill, 168, 169
 GE Additive, 161
 General Data Protection Regulations, 30
 General Electric (GE), 65
 acquisition of Alstom's heavy-duty gas turbine business, 163
 General Motors (GM)
 cost of entry to new markets, 29
 proposed merger of Allison and ZF Friedrichshafen, 2–3, 145
 Gene therapy
 Ciba-Geigy-Sandoz merger and, 156–158
 US patents citing, 158, 266n57
 Genzyme, acquisition of Novazyme Pharmaceuticals, 3, 148–149
 Gilead Sciences, 151–152
 GitHub, 32
 Glaxo, 161
 GlaxoSmithKline (GSK)
 proposed merger with Novartis, 150, 155
 Rotavirus vaccine by, 151
 Glaxo Wellcome (GW), 161
 Glaxo Wellcome (GW)–SmithKlineBeecham merger, 151–152, 162
 Google. *See also* Google comparison shopping services case
 ability and incentive to disadvantage firms that compete, 242–243
 acquisitions, 31–32, 33, 34
 Android phones, 19, 223–224
 benefit of data troves for, 25
 Chrome browser, 182, 186, 223, 269n14, 272n72
 comparison shopping service, 29
 FTC on changes to search engine, 3
 internet searching using, 197–199
 overtaking Yahoo! and AltaVista, 19
 search-based advertising and, 32
 use of Java, 272n60
 Google comparison shopping services case, 10, 11, 24, 195–205, 240
 coercion, NEST or rule of reason and, 214–216
 FTC and European Commission on, 202–205, 214–216
 market power in organic search, 199–202
 “Panda” update, 198–199, 214–216, 273n6
 precedents in *Lorain Journal* and *Otter Tail*, 217–218
 primer on Internet search, 197–199
 Google Flights, 33, 204
 Google Maps, 198
 Google Mobile Services, 223
 Google Shopping, 195, 196
 Graphical user interface (GUI), 72
 Graphics processing units (GPUs), 28, 210–211
 Green Cross Korea (GC Pharma), 151
- Halli Labs, 32
 Hard disk drive (HDD) manufacturers
 innovation and competition between, 118–119
 study of hypothetical mergers in, 124
 Hard disk drives (HDDs), established companies keeping old design for, 71–72
 Hard switch, 205–209
 Hart-Scott-Rodino (HSR) Act, 34, 79
 notification requirements, 122
 Hart-Scott-Rodino (HSR) value thresholds, 152, 238, 262n47
 HeartWare, challenge to proposed merger with Thoratec, 101, 142–145
 Heraeus Electro-Nite, merger with Midwest Instrument Co., 152–153
 Herfindahl-Hirschman Index (HHI), 165, 268n92
 Herpes infection vaccine, 152
 High-technology economy
 aggressive competition against startups and acquisition of potential competitors, 5
 characteristics of, 15–30
 concern that competition is not working for, 1
 expenditures on R&D, 13
 mergers in, 80, 81
 need for more aggressive antitrust enforcement, 30–35
 High-technology economy, competition policy for, 13–39
 antitrust enforcement for innovation and, 4–5
 competition and, 1–2

- High-technology economy (cont.)
 complements, interoperability, and standards require different approaches to evaluate competition, 26–28
 differences in high-technology economy, 15–30
 high-entry barriers for high-tech industries, 16–17
 high-tech firms have low cost to integrate new markets and exclude competition, 29–30
 information critical for high-tech economy, 24–26
 innovation can destroy incumbents in, 15–16
 innovation in the US economy and, 13–15
 issues for applying antitrust law to innovation in, 35–39
 many high-tech firms are platforms, 20–24
 network effects that can entrench incumbents, 17–20
 question of need for more aggressive antitrust enforcement, 30–35
 High-technology firms, acquisition of potential competitors, 7–8
 Hoechst Marion Roussel, 157
 Holdup, integration and, 186
 Horizontally differentiated products, product innovation incentives for, 51–52
 Horizontal Merger Guidelines, 7, 82, 83–86, 99
 Horizontal mergers, 78
 Hospira, 162–163
 Hotels.com, 204
 Hycamptin, 151, 152
- iAd, 34
 IAV, 87
 IBM, 21
 assisting rivals under European antitrust law, 176
 competition with Microsoft Windows, 168
 compulsory licensing consent decree and, 132, 133–134, 239
 entry points for competitors and, 190–191
 interoperability standards and, 27, 219
 plug-compatible manufacturers and, 207–208, 209
- IL-1, US patents citing, 159
 IL-1 inhibitors, 159
 IMDb, 32
 Immunex, proposed merger with Amgen, 158–159
 Implementers, development of standards covered by proprietary intellectual property rights and, 224–225
 Import competition, 115–116, 117
 Impossibility theorem, Arrow's, 229
 Incremental innovation, 92
 drastic innovation *vs.*, 121–122
 Incumbents, patenting and, 118–119
 Industry concentration
 innovation and, 108, 110, 116–117, 136
 profit from innovation and, 6
 Industry-innovation connection, unraveling, 108–112
 Industry privatizations, effect of new competition on innovation, 114
 Industry structure
 R&D investment and, 56, 112, 116–117
 stepwise innovation and, 61–62
 Industry studies, 118–122
 durable goods, 119–121
 incremental *vs.* drastic innovation, 121–122
 R&D “races,” 118–119
 Industrywide compatibility with standards, efforts to disrupt, 222–223
 Inflecta, 162
 Infliximab (Remicade), 162, 163
 Information, critical to high-tech economy, 24–26
 Informational standards, 219
 Information spillovers, R&D investment incentives and, 58
 “Innovate to sell,” 63
 Innovation
 antitrust enforcement decisions and, 2
 antitrust law applied to, 35–39
 antitrust treatment of product designs and, 10–11, 183, 195–197, 205–218
 Arrow replacement effect and monopoly in, 47–50
 codetermination with firm size and competition, 109–110
 competition, market structure, and, 112–118
 compulsory licensing and industry, 132–135

- conventional analysis suitable for some monopolization cases, 188–189
- cumulative, 47, 55, 56–57, 64–68, 254n20
- defined, 2
- difficulty of predicting, 188
- disrupting industries, 15–16
- drastic, 46, 74, 121–122
- effect of mergers on, 124–125
- effect of new competition on, 114–116
- emphasis in Horizontal Merger Guidelines on, 83–84
- evaluating effectiveness of remedies for, 241–242
- incremental, 46, 92, 121–122
- by incumbents and new entrants, 118–119
- interoperability is critical for, 191–192
- inventors erecting barriers to future, 65
- measurement of, 109
- mergers in high-tech and allegation of harm to, 80–81, 237
- mergers in high-tech industry and, 136
- monopoly power and, 41
- predatory, 11, 205
- productivity *vs.*, 112
- radical, 74–75, 92
- R&D competition and, 58
- R&D for buyout and, 56
- relying on validated presumptions to assess effects of, 237
- royalties for first- and second-generation, 66–68
- Schumpeter on imperfectly competitive markets and, 41
- simultaneous, 58
- socially beneficial, 207
- standards are critical for, 191–192
- stepwise, 60–62
- unilateral competitive effects to suppress, 87
- US antitrust litigation against Microsoft and, 177–178
- in US economy, 13–15
- Innovation cases, what makes “good,” 101–105
 - acquisition not necessary to incentivize innovation, 105
 - expectation of large future price effects, 104
 - innovations are new product for which appropriation is high, 102–103
 - intrafirm technological spillovers are low, 103
 - merger creates or enhances replacement effects, 102
 - merging parties do not have strong innovation incentives independent of the competition, 104–105
 - merging parties likely innovators in near term, 104
 - relevant research and development market highly concentrated, 101–102
- Innovation-centric competition policy, 2, 235–244
 - antitrust authorities should evaluate effectiveness of remedies for innovation, 241–242
 - antitrust authorities should not emphasize market definition to analyze innovation and future price competition, 236
 - antitrust authorities should rely on validated presumptions to assess innovation effects, 237
 - compulsory licensing can be effective tool to promote innovation, 239–240
 - courts should increase scrutiny of acquisitions that eliminate potential competitors, 238–239
 - courts should require evidence of benefits from proposed mergers or acquisitions, 237–238
 - courts should require evidence of substantial foreclosure to prevent exclusionary conduct, 239
 - should antitrust enforcement break up big tech, 242–244
 - truncated rule of reason is tool to assess allegations of anticompetitive innovation, 240–241
- Innovation competition
 - evaluating, 86–92
 - structural merger remedies for, 149–155
- Innovation dynamics, 55–56, 57–64
 - bidding for R&D assets, 62–64
 - patent races, 59–60
 - stepwise innovation, 60–62
 - two-period models of R&D and price competition, 57–59
- Innovation effects, predicting alleged, 39
- Innovation enforcement pyramid, 163
- Innovation impact effect, 257n23

- Innovation incentives, 6
 competition and, 7, 41–52, 56–64
 Cournot complements effect and, 27
 for durable goods, 52–53
 interaction of antitrust laws with
 intellectual property laws and, 24–25
 intrafirm technological spillovers and,
 90–91
 mergers and, 76, 87–89
 monopoly power and, 43–44
 right model of, 76
 rivalry and, 91–92
 role of antitrust enforcement in
 preserving, 165–166
 stepwise innovation and, 61–62
 Innovation incentives effect, 257n23
 Innovation incubators, role incumbents
 may play as, 73
 Innovation market, 99. *See also* Research
 and development market
 defined, 2
 unconditional merger challenge and, 145
 Innovation spaces, 165
 Innovators, development of standards
 covered by proprietary intellectual
 property rights and, 224–225
 Innovator's dilemma, 71–72, 75
 Instagram, acquisition by Facebook, 32,
 33–34, 35, 243
 Integration, holdup and, 186
 Intel Corporation, 27, 28, 48, 73, 133
 acquisitions, 33
 competition and innovation in micro-
 processors and, 120–121
 design change and, 276n51
 FTC complaint against, 210–211
 Intellectual property (IP) laws, antitrust
 laws interacting with, 24–25
 Intellectual property (IP) protection, as
 barrier to new competition, 16
 Intellectual property (IP) rights
 appropriation and, 102–103
 compulsory licensing and, 108, 130,
 132–135, 137, 141, 156, 239
 cumulative innovation and, 56–57,
 254n20
 design of, 65–67
 efforts to capture value from standard
 by exerting proprietary, 224–228
 standard-setting process and, 12,
 224–228
 Interindustry econometric studies,
 112–118
 summary of, 117
 International Committee for Information
 Technology Standardization, 277n7
 International Electrotechnical Commis-
 sion (IEC), 220
 International Organization for Standards
 (ISO), 220
 International Telecommunications Union
 (ITU), 220
 Internet Engineering Task Force (IETF),
 220, 276n5
 Internet Explorer (IE) web browser, 29,
 272n72
 investigation of Microsoft conduct
 regarding, 3, 10
 tying to Windows, 10, 169–170, 171, 172,
 175, 177, 179
 Internet search, primer on, 197–199
 Interoperability
 antitrust policy for standards/conduct
 affecting, 12, 219
 European Commission on Microsoft
 and, 175–176, 180–181
 evaluation of competition and, 27–28
 innovation and, 191–192
 product designs defeating, 208
 Intrafirm technological spillovers,
 89–91
 innovation cases where low, 103
 measurement of, 90
 mergers, innovation incentives, and,
 95, 96
 Inverted-U relationship between
 competition and innovation, 62, 114
 Invite Media, 32
 iPhones, 19, 210
 ITA Software, 32, 33, 201
 Ixifi, 163
 Jackson, Penfield, 171, 172, 173, 174, 179,
 186, 187
 Java programming language, 27, 181
 Google's use of, 272n60
 Microsoft and, 168, 169, 171, 172, 173,
 187
 Java standard, Microsoft's efforts to
 splinter, 182–183, 191, 222–223
 Java technologies, 269n8
 Jobs, Steve, 48, 210

- Joint Electron Device Engineering Council (JEDEC), 220, 226–227
- Joint ventures, standard development and, 227–228
- Kaggle, 32
- Kayak, 33, 204
- Keystone Sensors LLC, 153
- Killer acquisitions, 35, 129, 137
- KLA-Tencor Corp., 146–147
- Kodak, 74, 212
- Konica, 134
- Labor productivity, 112
- Lam Research Corp., 146–147
- Land, Edwin, 72
- Lattice, 32
- Left ventricular assist devices (LVADs), 142–144
- Lerner Index, 113–114, 260n17
- Licensing, compulsory. *See* Compulsory licensing
- Licensing, effects of compulsory licensing of patents on, 156
- Line extensions, 213
- LinkedIn, 18, 26
- Linux, 186
- Linux operating system kernel, 221, 224
- Litton, 134
- LiveRail, 32
- Lockheed Martin, 147
- London International Stock Exchange, 113
- Lorain Journal v. United States*, 217–218
- Lucent, 131
- Managerial incentives, 69–71
- Marginal cost
and Arrow model of R&D investment, 46–47
and high-tech industries, 16
prices close to marginal cost, 17
and two-sided platforms, 21–22
- Market definition, 5
analysis of innovation and future price competition emphasizing, 236
antitrust market, defined, 36–37
Google and, 199
obstacle to innovation-centric competition policy, 5, 36
- Market disruptions, evaluating mergers and, 86–87
- Market power
exercising by raising price above marginal production cost, 113
Google and, 199–202
innovation and, 110
measurement of, 111
R&D investment and, 113
- Markets, high-tech firms integrating into, 29–30
- Market shares, 5
analysis of innovation and future price competition emphasizing, 236
innovation by firms with large, 15, 113
market power and, 201, 206
structural presumptions based on, 39
- Market structure, patenting and, 118
- Maxtor, 73
- McDonnell Douglas, 147–148
- Measurement, of innovation, 109–112
- Medtronic, 144–145, 150, 162
- MEK-inhibitor, 155
- Mercedes-Benz, 87
- Merck, 151
proposed joint venture with Pasteur-Mérieux, 161
- Merger challenges in high-tech industries, 79–81
- Merger enforcement, 122–123
contemporary weakness in, 31
- Merger enforcement for innovation, 77–105, 139–166
agency guidance for innovation, 83–86
compulsory licensing as merger remedy, 155–161
evaluating innovation competition, 86–92
- Genzyme acquisition of Novazyme unchallenged, 148–149
- innovation enforcement at European Commission, 161–165
- introduction, 139–141
- lessons for merger policy for innovation, 165–166
- overlapping R&D mergers, 95–101
- product-to-project mergers, 92–94
- project-to-project mergers, 94–95
- structural merger remedies for innovation, 149–155
- unconditional merger challenges, 142–148
- what makes a “good” innovation case, 101–105

- Merger propensity, 126–127
- Mergers. *See also* Acquisitions
- bidding for R&D assets and, 63–64
 - courts should require evidence of benefits from, 237–238
 - courts should require scrutiny of mergers that eliminate potential competitors, 238–239
 - data and competition concerns regarding, 25–26
 - horizontal, 78
 - innovation and, 38–39, 76, 124–125, 136, 236, 237
 - R&D investment and, 8, 123–125, 126
 - reduction in competition *vs.*, 91
 - studies of, 122–130
 - studies of in pharmaceutical industry, 125–130
 - technological spillover and, 59
 - timing of antitrust enforcement decisions, 77–78
 - transforming, 126–127
 - vertical, 78, 256n3
- Metastandards, 219
- MetroPCS, 84–85
- Microprocessor industry, competition and innovation in, 120–121
- Microsemi Corp., 148
- Microsoft. *See also* *US v. Microsoft*
- acquisitions, 5, 32
 - Apple's success and, 19
 - compulsory licensing and, 240
 - cost of entry to new market, 29
 - cross-platform network effects and, 21
 - efforts to disrupt industrywide compatibility with standard, 222–223
 - interoperability standards and, 27, 28
 - LinkedIn acquisition, 26
 - as technology platform, 20
 - tying Internet Explorer to Windows, 10, 169–170, 171, 172, 175, 177, 179
 - tying Windows Media Player to Windows, 174–176
 - violation of Sherman Act and, 5, 171–172, 179, 182, 223
 - Windows operating system, 167–170
 - Yahoo! and, 84
- Microsoft and innovation harm from exclusionary conduct, 167–193
- analysis of final judgment, 184–186
 - economic assessment of US and EC antitrust litigation against Microsoft, 176–184
 - European Commission and, 174–176
 - introduction, 167–171
 - Microsoft Edge, 272n72
 - Microsoft Office, 185
 - Middleware, 168. *See also* Applications
 - barrier to entry
 - threat to Microsoft from Navigator, 181–182
 - Midwest Instrument Co., merger with Heraeus Electro-Nite, 152–153
 - Minco, 153
 - Minimum quality or safety standards, 219
 - Minolta, 134
 - Mixed bundling, 272n62
 - Mobbo, 34
 - Mobileye, 33
 - Modification of Final Judgment (MFJ), 131
 - Monopolies and Mergers Commission (UK), 114
 - Monopolist, incentive to invest in cost-reducing innovation and, 45–53
 - Monopolization, compulsory licensing to remedy, 130
 - Monopoly power
 - Arrow replacement effect and, 6, 41, 108
 - coercion and, 207
 - innovation and firm with, 41
 - innovation incentives and, 43–44
 - market share and, 15
 - network effects and, 17
 - portfolio effects and, 52
 - preemption incentives and, 48
 - Schumpeter and, 6, 43
 - standard setting and, 222–224, 231
 - Monopsony, 28
 - Monsanto, 165
 - Moore, Gordon, 133
 - Motion Picture Experts Group (MPEG), 220
 - Motorola Mobility, 32
 - Mozilla, 269n14
 - MySpace, 19
- National Electrical Code, 228
- National Fire Prevention Association (NFPA), 228

- National Institute of Standards and Technology (NIST), 220
- Nervana Systems, 33
- Nest, 32
- Netscape Navigator, 10, 269n14
importance of protecting nascent competition and, 187–188
Microsoft's attempts to suppress, 168–170
as threat to Microsoft, 177, 178, 181–182, 184
- Network effects, 4, 5–6
cross-platform, 21
excess inertia and, 18, 206–207, 211
high-tech industries entrenching incumbents and, 17–20
insufficient friction and, 18
interoperability and, 28
in personal computer market, 178–179
product transition and, 207
- Network externalities, 248n8. *See also* Network effects
- Newton, Isaac, 64
- NexTag, 195
- Nielsen Holdings, 25–26, 94
- No economic sense test (NEST), 209–211
for Google Shopping case, 214–215
- Nokia, 32, 131
- Nokia Bell Labs, 131
- Nondiscrimination commitment, FRAND licensing and, 233
- Nonexclusive license, 68, 132, 140, 156, 263n1
- Northrop Grumman, 147
- Novartis, 150, 157, 162
- Novazyme Pharmaceuticals, acquisition by Genzyme, 3, 148–149
- Nucleus, 31
- Oculus VR, 32
- Ohio v. American Express*, 23, 24
- Oligopoly
cost-reducing innovations in, 44
preemption incentives and, 48–49
- OMAX Corp., proposed merger with Flow International, 159–160
- Onavo, 250n51
- One monopoly profit theory, 190
- Onercept, 266n58
- Open Office XML, 182
- Open standard, 28, 220–221
- OpenTable, 21, 204
- Organizational capabilities, new product/service requirements and, 73–74
- Organizational failures, adjustment costs and, 71–75
- Orphan Drug Act, 149
- OSI Pharmaceuticals, 152
- OS/2 Warp, 168, 268n6
- Otter Tail Power v. United States*, 217–218, 276n60
- Overlapping R&D mergers, 95–101
- Panasonic, 134
- Panda, Navneet, 273n6
“Panda” update, 198–199, 214–216, 273n6
- Pasteur-Mérieux-Merck proposed merger, 161
- Patent acquisitions, 36–37
- Patent damages, rules for, 234
- Patent data, interindustry econometric studies using, 113–117
- Patent pools, 233
- Patent races, 55–56, 59–60, 254n10
spillover effects and, 253n7
- Patents. *See also* Compulsory licensing
effects of mergers in pharmaceutical industry, 127–128
market structure and patenting, 118
as measure of innovation, 109
standards-essential, 224, 232–233
- Patent thickets, 16, 225
- Personal computer operating systems
cross-platform network effects, 167–168
- Pfizer, 151
acquisition of Hospira, 162–163
- Pharmaceutical industry
acquisitions, 34–35
bidding for R&D assets, 62–64
hard switch and, 206, 207
rule of reason analysis and, 213, 215
study of mergers and acquisitions in, 125–130
- Philadelphia National Bank* decision, 99
- Photography, transition from film to digital, 74
- Picasa, 32
- Platform market
entry barriers in, 21
exclusionary contracting, 23
Google Shopping case and, 196

- Platforms, 4. *See also* Two-sided market competition, 249n24
 definition of platform businesses, 249n20
 exclusionary conduct and, 22–23
 high-tech firms as, 7, 10, 12, 15, 20–24
 market definition, 249n25
 two-sided market analysis and, 23, 190
- Poisson discovery probability, 253n5
- Polaroid, 72, 74
- Pompe disease, 148–149, 264n25
- Potential competition
 acquisitions that eliminate potential competitors, 238–239
 actual potential competition, 251–252n75
 antitrust law and potential competition, 37–38
 perceived potential competition, 251–252n75
- Predatory innovation, 11, 205
- Preemption, 6
 innovation by incumbents and new entrants and, 119
 Microsoft case and, 178
 radical innovation and, 74
 value of, 253n17
- Preemption incentives
 alternative entry paths and, 253n17
 and bidding for acquisition targets, 129
 competition, 48–50
 in a dynamic merger model, 119
 maintaining profits and, 73
- Price-centric antitrust enforcement, 2, 5, 14, 36, 235
- Price competition
 antitrust decisions and, 3, 4
 compulsory licensing and, 132–135
 overlapping R&D mergers and, 95–96
 product-to-project mergers and, 93
 project-to-project mergers and, 94
 rivalry and, 58
 two-period model of R&D and, 57–59
- Price coordination
 by incumbent monopolist, 50–51
 portfolio effects and, 52
- Price-cost margins, platforms serving populations with different, 20–24
- Price effects, innovation cases and expectation of large, 104
- PriceGrabber, 195
- Prices
 for complements, 26–27
 exercising market power by raising, 113
 harm to innovation and, 81–82
 R&D investment in microprocessor industry and, 121
- Privacy
 as antitrust concern, 1, 29, 242
 compulsory licensing and, 239–240
 high-tech economy and, 29–30
 regulation, 244
- Product design, 195
 antitrust policy for exclusionary, 205–216
 antitrust treatment of, 10–11
 competition and, 202, 204–205
- Product hopping, 213, 215
- Product improvement, stepwise innovation and, 60–61
- Product innovations, intrafirm spillovers and, 91
- Production
 Arrow replacement effect and, 47–50
 effect of competition on innovation greater for firms at frontier of efficient, 8
- Productivity, innovation *vs.*, 112
- Productivity growth, innovation and, 112
- Product overlaps, termination of R&D projects postmerger and, 129
- Product portfolio and profitability of innovation, 47, 50–53
- Product-to-project mergers, 92–94
 potential harm to innovation and, 96, 97, 99
- Profit sacrifice, 209
- Project-to-project mergers, 94–95
 potential harm to innovation and, 97
- Propensity method, 126–127
- Proprietary intellectual property rights, efforts to capture value from standard by exerting, 224–228
- Proprietary standard, 221
- Quickoffice, 32
- Quidsi, 33, 251n56
- Radical innovation, 74–75, 92
- Radio technologies, pooling and cross-licensing, 65
- Rambus, as participant in JEDEC, 226–227, 234

- Rapid prototyping (RP) printing systems,
160–161
US patents on, 266–267n67
- RCA, 74, 254n19
- R&D cost-savings, mergers and, 38, 84
- R&D decisions, organizational limitations
and, 71, 75
- R&D expenditures
accounting for, 111
as barrier to entry, 16–17
empirical studies of competition and,
113–122
empirical studies of compulsory
licensing and, 130–135
empirical studies of mergers and,
122–130
intellectual property right design and, 66
as measure of industry concentration,
101
as measure of innovation output, 109,
124
in microprocessor industry, 121
as percent of revenues for US industries,
13, 14
in pharmaceutical industry, 126–130,
207
proposed merger of Applied Materials
and Tokyo Electron and, 145–146
in telecommunications industry, 132
- R&D incentives, 129–130
two-period model of price competition
and, 57–59
- R&D intensities, high-tech economy
and, 13
- R&D investment
appropriation and, 44–45
to facilitate buy-outs, 56, 105
import competition and, 115–116, 117
incentives for, 110
industrial structure and, 56
managerial incentives and, 69–71, 75
market power and, 113
mergers and, 123–125, 126
pricing in microprocessor industry and,
121
- R&D projects
overlapping R&D mergers and, 95–101
pharmaceutical mergers and, 128–129
- R&D “races,” 118–119
- Reagan, Ronald, 131
- RealFace, 32
- re Apple iPod iTunes Antitrust Litigation*,
208
- Recombinant DNA technologies,
Amgen-Immunes merger and, 158–159
- Reduced instruction set computing
(RISC) microprocessors, 74
- Regeneron, 159
- Replacement effects, innovation cases and
creation or enhancement of, 102.
See also Arrow replacement effect
- Research and development market,
99–100, 236
innovation cases and highly concen-
trated, 101–102
- Reuters, 25, 26
- Revenues, as measure of innovation, 109
- Rhône-Poulenc Rory (RPR), 156, 157
- Rivalry
innovation incentives and, 57–58, 91–92
patent races and, 56
price competition and, 58
R&D competition and, 60
- Robert Bosch, 87
- Rotavirus vaccine, 151
- Royalty, for first- and second-generation
innovations, 66–68
- Royalty-stacking, 233
- Rule of reason analysis, 205, 211–214
of Google Shopping case, 215–216
truncated, 11, 196–197, 213–214,
240–241
- Salesforce.com, 182
- Samsung, 267n79
- Sandoz, 95
- Sanofi, 157
- Schumpeter, Joseph, 15
cited in *US v. Microsoft* decision, 177
consequences of limited appropriation
and, 41, 42–45
- Schumpeterian appropriation effect, 8,
55, 59
in stepwise innovation model, 61
- Schumpeterian theory of imperfect
competition, 6, 41–43
- Science Policy Research Unit (SPRU),
110–111, 113
- SCM Corp. v. Xerox Corp., 36–37
- Seagate, 73, 267n79
- Search algorithms, Google changes to,
197, 198

- Search engine results page (SERP), 195–196, 197, 199
- Search engines. *See also individual search engines*
- Google Shopping case and changes to Google algorithms, 195–196
 - high entry barriers, 16
 - price competition and, 21–22
- Second request, for mergers, 79
- Semicoa, Inc., 148
- Semiconductor industry
- measuring innovation in, 109
 - proposed merger of Applied Materials and Tokyo Electron, 145–148
- Semiconductor photolithography, 74
- Serono, 159, 266n58
- Sharp, 134
- Shazzam, 32
- Sherman Antitrust Act, 3, 4, 5
- AT&T breakup and, 131
 - Microsoft's violation of, 171, 172, 179
- Shockley Semiconductor Laboratory, 73
- Shopping.com, 195
- Shopzilla, 195
- Simultaneous innovation, 58
- Skype, 32
- SmithKlineBeecham, merger with Glaxo Wellcome, 151–152, 162
- Snapchat, 31
- Snap Inc., 31
- Social networks, network effects and, 17, 18
- Social value, 42, 46, 207, 252n12
- Soft switch, 206
- Sony Corporation, 161
- Spectranetics Corporation, 150
- Spillovers
- industry productivity and, 252n9
 - information, 58
 - interfirm technological, 90
 - intrafirm technological, 90–91, 103
 - technological, 45, 59, 89–90
- Standard Oil, 239
- Standard & Poor's (S&P) 500 Index, 16
- Standards
- competition policy for (*see* Competition policy for standards)
 - evaluation of competition and, 27–28
 - importance for innovation, 191–192
 - informational, 219
 - minimum quality or safety, 219
 - open, 28, 220–221
 - proprietary, 221
 - technical, 219
 - types of, 219
- Standards development organizations (SDOs), 219–222
- antitrust concerns from collective conduct in, 228–232
 - conflict between implementers and innovators, 225
 - coordination in determination of FRAND patent-licensing obligations, 229–232
- Standards-essential patents (SEPs), 224
- policies to promote FRAND licensing, 232–233
- Standards estoppel, 234
- Standard setting, 12, 27–28, 219–222
- Standard-setting consortia, 220
- Standards wars, 221
- Statin drug market, 103
- Statistical limitations, testing innovation relationships and, 111
- Stepwise innovation model, 60–62, 254n11
- Stereolithography, 266n67
- St. Jude Medical, 145
- Stratasy, 161
- Structural merger remedies for innovation, 149–155
- American Home Products–American Cyanamid, 151
 - Glaxo Wellcome–SmithKlineBeecham, 151–152
 - Heraeus Electro-Nites–Midwest Instrument Co., 152–153
 - Nielsen Holdings–Arbitron, 153–155
 - Novartis–GSK, 150, 155
- Structural remedies, 140. *See also* Divestiture
- as antitrust remedy for big tech, 242–244
 - proposed in *US v. Microsoft* judgment, 172–174, 185–186
- Sun Microsystems, 171, 173, 182–183, 222, 277n7
- Synchronous dynamic random access memory (SDRAM) devices, 226
- Syngenta, 162, 164
- Tacit collusion, 87
- Tandberg, 28

- tbh, 32
- Technical standards, 219
- Technological areas, ease of integrating into related, 192–193
- Technological opportunity, appropriation and, 110
- Technological spillovers
appropriability and, 89–90
interfirm, 90
intrafirm, 90–91, 103
mergers and, 59
R&D investment and, 45
- Technological tying, 183
- Technology, disruptive, 255n33
- Technology overlaps, termination of R&D projects postmerger and, 129
- Telcordia Technologies, 131
- Telecommunications Act (1996), 132, 185
- Telefunken, 65
- Telephone networks, network effects and, 17, 18
- TelePresence Interoperability Protocol (TIP), 28
- Ten blue links model, 197
- Textile firms, effect of competition on innovation by, 115–116
- Theory of the second best, 248n7
- Thomson, 25, 26
- Thoratec, proposed merger with HeartWare, 101, 142–145
- 3D Systems–DTM Corp. merger, 160–161
- 3GPP, 220
- T-Mobile, 84–85
- TNF inhibitors, 159
US patents citing, 159
- Tokyo Electron, challenge to proposed merger with Applied Materials, 145–148
- Topoisomerase I inhibitor, 151–152, 162
- Toshiba, 134
- Total factor productivity, 112, 260n10
- Trading with the Enemy Act, 134–135
- Transforming mergers, 126–127
- Transistor radio technology, 74
- Travelocity, 204
- Treaty on the Functioning of the European Union, 4, 203
- TripAdvisor, 199, 204
- Truncated rule of reason, 11, 196–197, 213–214
to assess allegations of anticompetitive innovation, 240–241
- Truncation bias, 124
- Two-period models of R&D and price competition, 57–59
- Two-sided market
for internet search, 196
platform as, 20, 23–24
- Two-sided market analysis, 23
for integration of Windows and IE, 179
for internet search and advertising, 199–200
platform competition and, 190
- Tying, 272n66
Internet Explorer to Windows, 10, 169–172, 175, 177, 179
rule of reason treatment for, 183–184
Windows Media Player to Windows, 174–176
- Unconditional merger challenges, 139, 142–148
Applied Materials–Tokyo Electron, 145–148
General Motors–ZF Friedrichshafen, 142
Thoratec–HeartWare, 142–145
- Underwriters Laboratories, 219
- Unilateral effects for innovation evaluating mergers and, 86–92
models of, 89, 258n37
overlapping R&D mergers, 95–101
product-to-project mergers and, 92–94
project-to-project mergers and, 94–95
- Unilateral effects theory, European Commission's use of, 164–165
- Unilateral price effects, from merger, 88–89, 100, 237
- United States economy, innovation in, 13–15
United States v. E. I. DuPont de Nemours, 36
United States v. Phila. Nat'l Bank, 259n51
- Universal Search, 197–198
- Universal serial bus (USB), 220
- Unix, 131, 186, 224

- US v. 3D Systems Corporation and DTM Corporation*, 266n64
- US v. Microsoft*, 9–10, 23, 171–174, 238
- economic assessment of, 176–184
- Final Judgment, 20, 174, 184–186
- harm alleged by Microsoft's actions, 3, 172
- issue of monopolization in, 227
- lessons from, 187–193
- middleware threat to, 181–182
- proposed structural remedy, 172–174, 185–186
- rule of reason analysis and, 211–212
- Value effect, innovation and, 63–64
- VDA (Verband der Automobilindustrie), 87
- Venture capitalists, kill zone of technologies and, 11, 31
- Verizon v. Trinko*, 176, 208, 217
- Versa Module Europa computer bus, 230
- Vertically differentiated products, product innovation incentives for, 51
- Vertical mergers, 78, 256n3, 263n15
- Verticals (specialized displays in internet search results), Google Shopping case and, 198, 204
- VESA SDO, 226
- VITA standards organization (VSO), 230–232
- Viviti Technologies, 267n79
- VL computer bus standard, 225–226
- VMEbus Manufacturers Group, 230
- Volkswagen AG, 87
- Vote stacking, in SDOs, 228–229
- Walmart, 243
- Waterjet cutting systems, Flow International–OMAX merger and, 159–160
- Waze, 32
- WeChat, 33
- Wellcome, 161
- Western Digital, 267n79
- Western Electric, 131, 262n49
- Westinghouse, 65
- WhatsApp, 32, 33–34
- Whole Foods, 33
- Wilshire 5000 stock market index, 31
- Windows operating system, 167–170
- Internet Explorer tied to, 10, 29, 169–172, 175, 177, 179
- Windows Media Player (WMP) tied to, 174–176
- Winner-take-all competition, 56, 57–58, 89, 178, 261n28
- Winner-take-most competition, 261n28
- World Trade Organization, 115
- World Wide Web Consortium (W3C), 220
- Wright, Wilbur and Orville, 65
- Wyeth, 151
- Xenova Pharmaceuticals, 152
- Xerography, 56
- Xerox Corporation, 51, 72
- compulsory licensing consent decree and, 132, 133–134, 239
- Xerox PARC, 72
- Yahoo!, 19, 84, 200
- Yelp, 199, 204
- YouTube, 32, 35
- Zagat, 32
- Zappos, 33
- Zeneca, 162
- Zetawire, 32

This is a section of [doi:10.7551/mitpress/12686.001.0001](https://doi.org/10.7551/mitpress/12686.001.0001)

Innovation Matters

Competition Policy for the High-Technology Economy

By: Richard J. Gilbert

Citation:

Innovation Matters: Competition Policy for the High-Technology Economy

By: Richard J. Gilbert

DOI: 10.7551/mitpress/12686.001.0001

ISBN (electronic): 9780262358637

Publisher: The MIT Press

Published: 2022

The open access edition of this book was made possible by generous funding and support from Arcadia – a charitable fund of Lisbet Rausing and Peter Baldwin



The MIT Press

© 2020 Massachusetts Institute of Technology

This work is subject to a Creative Commons CC-BY-NC-ND license.

Subject to such license, all rights are reserved.



The open access edition of this book was made possible by generous funding from Arcadia—a charitable fund of Lisbet Rausing and Peter Baldwin.



This book was set in Palatino by Westchester Publishing Services.

Library of Congress Cataloging-in-Publication Data

Names: Gilbert, Richard J., 1945- author.

Title: Innovation matters : competition policy for the high-technology economy / Richard J. Gilbert.

Description: Cambridge, Massachusetts : MIT Press, [2020] | Includes bibliographical references and index.

Identifiers: LCCN 2019039525 | ISBN 9780262044042 (hardcover)

Subjects: LCSH: High technology industries. | Competition. | Antitrust law--Economic aspects. | Consolidation and merger of corporations--Law and legislation--Economic aspects.

Classification: LCC HC79.H53 G56 2020 | DDC 338.8/2--dc23

LC record available at <https://lcn.loc.gov/2019039525>